Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

A$70m capital raising & Lantheus investment approved at EGM

Wednesday, August 14, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has successfully approved a capital raising of A$70 million and secured an investment from Lantheus at their Extraordinary General Meeting (EGM). This funding is expected to bolster their clinical programs, particularly in the development of their therapeutic candidates. The company has also received positive updates across its various clinical initiatives.

Market Sentiment Analysis

POSITIVE FACTORS

  • Approval of A$70m capital raising indicates strong investor confidence.
  • Lantheus investment approval supports future growth opportunities.
  • Positive clinical updates across multiple programs enhance company reputation.

Full Press Release Details

• Announcements
• August 14, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• December 22, 2022
• Announcements
• September 28, 2023
• Announcements
• August 24, 2024
• Announcements
• July 16, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What was approved at the EGM?

The EGM approved a capital raising of A$70 million and an investment from Lantheus.

How will the capital raising benefit Radiopharm?

The capital raising is expected to support Radiopharm's clinical programs and future growth.

What is the significance of the Lantheus investment?

The Lantheus investment is seen as a strong endorsement of Radiopharm's potential.

What updates were provided by Radiopharm?

Radiopharm provided positive clinical updates across multiple programs during the announcement.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Lantheus capital raising clinical updates
Last updated: Aug 14, 2024